ATLANTA — Ivosidenib or enasidenib used in combination with standard induction therapy provided encouraging response rates and appeared well tolerated among patients with acute myeloid leukemia, according to findings presented at the ASH Annual Meeting and Exposition.
The addition of ivosidenib (AG-120, Agios) or enasidenib (Idhifa; Celgene, Agios) to induction chemotherapy provided particularly promising results among patients with secondary AML, many of whom received treatment with hypomethylating agents.
This activity is supported by an educational grant from Merck & Co., Inc.
At Issue: Melanoma Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.